vs

Side-by-side financial comparison of Arcturus Therapeutics Holdings Inc. (ARCT) and MODIV INDUSTRIAL, INC. (MDV). Click either name above to swap in a different company.

MODIV INDUSTRIAL, INC. is the larger business by last-quarter revenue ($11.1M vs $7.2M, roughly 1.5× Arcturus Therapeutics Holdings Inc.). On growth, MODIV INDUSTRIAL, INC. posted the faster year-over-year revenue change (-5.6% vs -68.4%). Over the past eight quarters, MODIV INDUSTRIAL, INC.'s revenue compounded faster (-3.8% CAGR vs -56.5%).

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

MODIV INDUSTRIAL, INC. is a U.S.-based industrial real estate enterprise focused on acquiring, owning and operating high-quality industrial properties mainly located in key logistics and distribution hubs across North America. It serves tenants from sectors including e-commerce fulfillment, manufacturing and third-party logistics, addressing rising demand for modern supply chain infrastructure.

ARCT vs MDV — Head-to-Head

Bigger by revenue
MDV
MDV
1.5× larger
MDV
$11.1M
$7.2M
ARCT
Growing faster (revenue YoY)
MDV
MDV
+62.8% gap
MDV
-5.6%
-68.4%
ARCT
Faster 2-yr revenue CAGR
MDV
MDV
Annualised
MDV
-3.8%
-56.5%
ARCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARCT
ARCT
MDV
MDV
Revenue
$7.2M
$11.1M
Net Profit
$1.2M
Gross Margin
Operating Margin
45.8%
Net Margin
11.0%
Revenue YoY
-68.4%
-5.6%
Net Profit YoY
3.1%
-22.0%
EPS (diluted)
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARCT
ARCT
MDV
MDV
Q4 25
$7.2M
$11.1M
Q3 25
$17.2M
$11.7M
Q2 25
$28.3M
$11.8M
Q1 25
$29.4M
$11.8M
Q4 24
$22.8M
$11.7M
Q3 24
$41.7M
$11.7M
Q2 24
$49.9M
$11.4M
Q1 24
$38.0M
$12.0M
Net Profit
ARCT
ARCT
MDV
MDV
Q4 25
$1.2M
Q3 25
$-13.4M
$1.0M
Q2 25
$-9.2M
$-2.0M
Q1 25
$-14.1M
$829.0K
Q4 24
$-30.0M
$1.6M
Q3 24
$-6.9M
$-587.0K
Q2 24
$-17.2M
$1.3M
Q1 24
$-26.8M
$3.7M
Operating Margin
ARCT
ARCT
MDV
MDV
Q4 25
45.8%
Q3 25
-96.3%
41.4%
Q2 25
-41.0%
9.8%
Q1 25
-57.3%
40.2%
Q4 24
-146.7%
45.4%
Q3 24
-25.8%
42.0%
Q2 24
-42.4%
44.6%
Q1 24
-80.0%
55.6%
Net Margin
ARCT
ARCT
MDV
MDV
Q4 25
11.0%
Q3 25
-78.4%
9.0%
Q2 25
-32.4%
-17.1%
Q1 25
-47.9%
7.0%
Q4 24
-131.8%
13.3%
Q3 24
-16.6%
-5.0%
Q2 24
-34.5%
11.6%
Q1 24
-70.5%
31.1%
EPS (diluted)
ARCT
ARCT
MDV
MDV
Q4 25
$0.02
Q3 25
$-0.49
$0.00
Q2 25
$-0.34
$-0.32
Q1 25
$-0.52
$-0.01
Q4 24
$-1.10
$0.07
Q3 24
$-0.26
$-0.18
Q2 24
$-0.64
$0.03
Q1 24
$-1.00
$0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARCT
ARCT
MDV
MDV
Cash + ST InvestmentsLiquidity on hand
$230.9M
$14.4M
Total DebtLower is stronger
$261.5M
Stockholders' EquityBook value
$214.0M
$162.7M
Total Assets
$271.1M
$476.5M
Debt / EquityLower = less leverage
1.61×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARCT
ARCT
MDV
MDV
Q4 25
$230.9M
$14.4M
Q3 25
$180.4M
$8.3M
Q2 25
$196.5M
$5.8M
Q1 25
$216.9M
$6.2M
Q4 24
$237.0M
$11.5M
Q3 24
$237.2M
$6.8M
Q2 24
$260.3M
$18.9M
Q1 24
$288.4M
$18.4M
Total Debt
ARCT
ARCT
MDV
MDV
Q4 25
$261.5M
Q3 25
$279.7M
Q2 25
$279.7M
Q1 25
$279.7M
Q4 24
$279.8M
Q3 24
$279.7M
Q2 24
$279.7M
Q1 24
$279.6M
Stockholders' Equity
ARCT
ARCT
MDV
MDV
Q4 25
$214.0M
$162.7M
Q3 25
$224.6M
$164.8M
Q2 25
$231.1M
$165.6M
Q1 25
$233.8M
$171.1M
Q4 24
$241.0M
$190.1M
Q3 24
$261.9M
$186.3M
Q2 24
$258.6M
$187.0M
Q1 24
$264.0M
$188.0M
Total Assets
ARCT
ARCT
MDV
MDV
Q4 25
$271.1M
$476.5M
Q3 25
$282.3M
$499.6M
Q2 25
$309.3M
$498.9M
Q1 25
$331.8M
$506.8M
Q4 24
$344.1M
$507.8M
Q3 24
$370.7M
$507.4M
Q2 24
$388.6M
$519.5M
Q1 24
$418.8M
$522.5M
Debt / Equity
ARCT
ARCT
MDV
MDV
Q4 25
1.61×
Q3 25
1.70×
Q2 25
1.69×
Q1 25
1.63×
Q4 24
1.47×
Q3 24
1.50×
Q2 24
1.50×
Q1 24
1.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARCT
ARCT
MDV
MDV
Operating Cash FlowLast quarter
$-74.3M
$15.0M
Free Cash FlowOCF − Capex
$-74.5M
FCF MarginFCF / Revenue
-1035.2%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
12.34×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARCT
ARCT
MDV
MDV
Q4 25
$-74.3M
$15.0M
Q3 25
$-17.2M
$4.1M
Q2 25
$-5.8M
$3.9M
Q1 25
$-35.1M
$3.0M
Q4 24
$-284.0K
$18.2M
Q3 24
$-23.8M
$5.1M
Q2 24
$-30.1M
$4.7M
Q1 24
$-5.6M
$3.0M
Free Cash Flow
ARCT
ARCT
MDV
MDV
Q4 25
$-74.5M
Q3 25
$-17.3M
Q2 25
Q1 25
$-35.3M
Q4 24
Q3 24
$-23.8M
Q2 24
$-30.5M
Q1 24
$-5.8M
FCF Margin
ARCT
ARCT
MDV
MDV
Q4 25
-1035.2%
Q3 25
-101.1%
Q2 25
Q1 25
-120.1%
Q4 24
Q3 24
-57.2%
Q2 24
-61.1%
Q1 24
-15.3%
Capex Intensity
ARCT
ARCT
MDV
MDV
Q4 25
3.2%
Q3 25
1.1%
Q2 25
0.0%
Q1 25
0.5%
Q4 24
0.0%
Q3 24
0.2%
Q2 24
0.7%
Q1 24
0.6%
Cash Conversion
ARCT
ARCT
MDV
MDV
Q4 25
12.34×
Q3 25
3.95×
Q2 25
Q1 25
3.68×
Q4 24
11.72×
Q3 24
Q2 24
3.55×
Q1 24
0.80×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons